Flash Report 2 minutesRegister for Free AccessCVS Pharmacy (CVS) 2Q16 Results: Mixed Quarter, but Company Raises Guidance Coresight Research August 2, 2016 Executive Summary CVS reported 2Q16 adjusted EPS of $1.32, up 8.3% year over year and ahead of guidance of $1.28–$1.31, beating the consensus estimate by two cents. The company reported revenues of $43.7 billion, up 17.6% year over year but missing the $44.3 billion consensus estimate. Growth was driven by the Pharmacy Services segment, whose revenues grew by 20.7% year over year, to $29.5 billion, due to higher pharmacy network claim volume and growth in specialty pharmacy. The company raised and narrowed its FY16 adjusted EPS guidance to $5.81–$5.89 from $5.73–$5.88 previously, though it lowered its GAAP EPS guidance due to debt extinguishment and acquisition-integration costs. Please Login to read the full report. Not a member? Register for a free user account. This document was generated for Other research you may be interested in: How US Consumers Are Shopping for Groceries: Analyzing Traffic, Ticket, E-Commerce and Private LabelM&A in US Apparel and Footwear: Strong Prospects To Redefine Portfolios and Bolster CapacityUsing the Coresight Research 3x3x3 Framework To Navigate a “Chutes and Ladders” Economy: Insights Presented at Golden Seeds 2023 Annual SummitRetail-Tech Landscape: Retail Media